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Recombinant Tissue Plasminogen Activator and
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Yong Woon Shim, Seung Min Kim, and Ji Hoe Heo
BACKGROUND AND PURPOSE: Combined intravenous (IV) and intra-arterial (IA) throm-
bolytic therapy may be faster and easier to initiate than monotherapy, and its recanalization
rate may be better as well. The sequential combination of recombinant tissue plasminogen
activator (rTPA) and urokinase (UK) has synergistic and complementary effects on clot lysis.
We prospectively evaluated the effectiveness and safety of sequential combination of IV rTPA
and IA UK in acute ischemic stroke.
METHODS: IV rTPA was administered to patients with acute stroke within 3 hours of onset.
Those whose condition had not improved at the end of rTPA infusion were further treated with
selective IA UK. We evaluated baseline and 30-day National Institutes of Health Stroke Scale
(NIHSS) scores and 90-day modified Rankin Scale scores.
RESULTS: Thirty patients were initially treated with IV rTPA; 24 were further treated with
IA UK. Four patients who had rapid reocclusion following initial successful IA therapy received
IV abciximab. Fourteen of 24 patients who underwent angiography had an effective perfusion
state of Thrombolysis in Myocardial Infarction grade 3 flow. Median baseline and 30-day
NIHSS scores were 18 and 2, respectively. Eighteen patients improved to a modified Rankin
scale score of 0 or 1 after 90 days. Symptomatic hemorrhage developed in two patients.
CONCLUSION: The strategy of using conventional-dose IV rTPA and the sequential combination
of IA UK in patients without an early clinical response to IV treatment was safe and feasible. This
strategy achieved high complete arterial recanalization rates and good functional outcomes.
Early and complete recanalization of an occluded
artery is the main therapeutic goal of acute isch-
emic stroke. Since the National Institute of Neuro-
logic Disorders and Stroke (NINDS) study (1) was
done, intravenous (IV) recombinant tissue plas-
minogen activator (rTPA) therapy within 3 hours
after the onset of symptoms has been widely used.
Despite the advantage of the rapid and easy initi-
ation of thrombolytic therapy, IV rTPA treatment
is limited by low recanalization rates, particularly in
larger proximal arterial occlusions (2, 3). Com-
pared with the IV approach, intra-arterial (IA)
thrombolysis is reported to have higher recanaliza-
tion rates and an extended therapeutic window (4–
6). However, IA thrombolysis is limited by the
delay to the initiation of treatment and the need for
specialized angiographic techniques.
The combined IV and IA approach has been
increasingly examined in pilot studies. This ap-
proach is reportedly feasible and safe, with a better
recanalization rate and potentially improved pa-
tient outcomes (7–11). In most of these studies,
rTPA was used for both IV and IA thrombolysis
with divided doses for the IV and IA treatments.
However, the combined use of thrombolytic agents
with different mechanisms may have an additive
and/or complementary effect. TPA and urokinase
(UK) are the native plasminogen activators in the
fibrinolytic system and have been used effectively in
stroke patients. They are known to have synergistic
and complementary effects in experimental studies
in vitro and in vivo and also in patients with acute
myocardial infarction when the agents are admin-
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istrated sequentially (12–17). In this pilot study, we
examined the efficacy and safety of a sequential
combination of IV rTPA and IA UK in patients
with acute ischemic stroke patients who presented
within 3 hours after the onset of symptoms.
Methods
Patient Selection
We prospectively enrolled consecutive patients with acute
ischemic stroke who were admitted to the neurology depart-
ment during a period of 21 months and who underwent throm-
bolysis. The institutional review board approved this study, and
informed consent was obtained from the patients or their
surrogates. The inclusion criteria for thrombolysis, based on
those of previous major thrombolysis trials, included ischemic
stroke with the planned initiation of IV thrombolysis within 3
hours after onset, patient age of 18–85 years, a National Insti-
tutes of Health Stroke Scale (NIHSS) score 4 (except for
isolated aphasia or hemianopia), normal or early signs on
nonenhanced brain CT scans without evidence of hemorrhage,
and obtainable informed consent.
Exclusion criteria were the following: a history of symp-
tomatic ischemic stroke within 6 weeks; a history of head
trauma within the previous 90 days; a history of surgery;
biopsy involving a major organ; recent or active hemorrhage;
trauma associated with internal organ injury or an ulcerative
wound within the previous 30 days; a history of an arterial
puncture at a noncompressible site within the previous 7
days; seizure at onset; a history of intracranial hemorrhage;
a clinical presentation suggestive of subarachnoid hemor-
rhage or septic embolism; systolic blood pressure 185 mm
Hg or diastolic blood pressure 110 mm Hg; bleeding dia-
thesis; a history of serious, advanced, or terminal illness;
rapidly improving neurologic signs; a clinical presentation of
a lacunar infarction; or a comatose state in suspected carotid
arterial stroke. Patients with an initial blood pressure above
the specified limits were excluded if aggressive treatment
was required to reduce their blood pressure below that level.
Laboratory exclusion criteria included an increased interna-
tional normalized ratio of 1.7, a history of heparinization
within the previous 48 hours, an elevated activated partial
thromboplastin time, platelet counts 100,000/mm3, a he-
matocrit level of 25%, or a glucose concentration 50
mg/dl (2.7 mmol/L) or 400 mg/dL (22.2 mmol/L).
Thrombolytic Therapy
V thrombolysis was performed by using rTPA (Actilyse;
Boehringer Ingelheim, Germany). A total dose of 0.9 mg/kg
was given, with a 10% loading bolus injection followed by a
continuous infusion over 60 minutes. Patients showing no
early clinical responses to IV rTPA at the end of rTPA
infusion (i.e., improvement of NIHSS score of 4) received
IA thrombolysis. When an occlusion of the intracranial ar-
teries was documented on diagnostic cerebral angiograms
obtained by using a 5F catheter (Headhunter cerebral cath-
eter; Cook, Bloomington, IN) via a femoral approach, super-
selective angiography was performed through a microcath-
eter. The tip of the microcatheter was imbedded in the face
of the thrombus by using an end-hole microcatheter (Excel-
sior; Target Therapeutics, Fremont, CA) or through the
thrombus by using a side-hole microcatheter (Micro-Soft
Stream; Target Therapeutics). UK (Yuhan, Seoul, Korea)
100,000 U was reconstituted in 5 mL of 0.9% normal sodium
chloride solution. This was manually infused in a pulsatile
injection manner at a rate of 15,000 U/min by using a 1-mL
syringe. UK 300,000 U was given initially, and angiography
was then performed. If recanalization was not achieved, an
additional 200,000 U was infused until recanalization oc-
curred. The maximum doses of UK were limited to 1,000,000
U. The recanalized arteries were reevaluated 20 minutes
later by means of repeat angiography to determine if the
arteries had maintained their patency. When a reocclusion
occurred, IV abciximab was administrated as a bolus at 0.2
mg/kg, and a subsequent infusion was given for 12 hours at
rate of 0.125 g/kg/min.
Assessment of Hemorrhagic Transformation and
Clinical Outcome
Nonenhanced brain CT scanning or MR imaging was per-
formed 24 hours after rTPA infusion and at any time when
clinical deterioration was noted or hemorrhage was suspected.
Hemorrhagic transformation (HT) was assessed by means of
CT and defined as areas of increased attenuation on nonen-
hanced scans. Symptomatic hemorrhage was defined as any
increase in the NIHSS score attributable to intracranial hem-
orrhage. Clinical assessments included baseline and 30-day
determinations of NIHSS scores, as well as modified Rankin
scale (mRS) scores at 90 days. One of two neurologists (K.Y.L.,
S.H.K.) who were not blinded to the angiographic findings
performed the assessments.
Statistical Analysis
The chi-square test was used to define the difference of HT
rate between the successful and unsuccessful recanalization
groups. P value .05 was considered significant.
Results
Demographic Data
Thirty consecutive patients (18 men, 12 women) with
a median age of 63 years (range, 47–82 years), were
enrolled. Twenty-five patients were admitted via the
emergency room, whereas five developed an acute
stroke during their admission for systemic illnesses
other than cerebrovascular disease. The median time
from onset to visit or discovery was 45 minutes. Nine
patients had cardioembolic sources, such as an atrial
fibrillation or a sick sinus syndrome.
Thrombolytic Treatment
IV rTPA was initiated at a median time of 2 hours
15 minutes (range, 60–210 minutes) from the onset of
stroke. All but five patients received a full dose of
rTPA (0.9 mg/kg). Early clinical improvement
(NIHSS score 4) at the end of the rTPA infusion
was observed in seven patients. However, the symp-
toms recurred in two of these patients at 7 and 2
hours after their initial improvement. Cerebral an-
giography was performed immediately after IA
thrombolysis in 24 patients and not in five patients
who had improved or in one patient in whom occlu-
sion of a cortical branch was suggested. The median
time from onset to the femoral arterial puncture was
3 hours 50 minutes (range, 60–310 minutes). Cerebral
angiography demonstrated occlusions of the proximal
middle cerebral artery (MCA) in nine patients, the
distal internal carotid artery (ICA) in four, the cervi-
cal ICA in two, the basilar artery (BA) in two, the
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distal MCA in one, and the posterior cerebral artery
(PCA) in one (Table 1). Occluding thrombi were not
found in five patients (three with stenosis of the
clinically relevant arteries and two with normal angio-
graphic findings). Finally, 16 patients were further
treated with IA UK. Those not treated with IA UK
FIG 1. Flowchart shows the sequential
combination of thrombolysis. Numbers in
parentheses are numbers of patients. TIMI
 Thrombolysis in Myocardial Infarction.













90 Day HTrTPA DSA Baseline 30 Day
1/59/F 120 270 800,000 Distal ICA 2 9 5 2 No
2/61/M 210 290 800,000 BA 3 28 1 0 No
3/53/F 60 120 500,000 M1 3 14 2 1 No
4/74/F 195 300 300,000 M2 0 22 0 0 Asym
5/76/F 170 260 500,000 M1 3 13 1 0 No
6/82/M 100 NA NA NA NA 30 0 0 No
7/62/M 75 110 700,000 M1 3 25 3 1 No
8/60/F 90 160 600,000 M1 2 19 10 4 Asym
9/52/M 90 160 NA M1 stenosis 3 8 0 0 No
10/47/M 90 60* 800,000 BA 3 15 0 0 No
11/48/M 130 210* NA Normal 3 7 2 0 No
12/78/M 175 NA NA NA NA 9 NA 6 No
13/74/F 120 240 800,000 M1 3 17 7 3 Asym
14/65/F 150 210 400,000 Distal ICA 0 22 25 5 Asym
15/63/M 145 210 800,000 M1 3 22 7 2 No
16/61/M 140 NA NA NA NA 7 1 1 No
17/78/M 105 205 NA Cervical ICA 0 19 NA 5 No
18/70/M 150 270 600,000 M1 2 23 9 2 No
19/81/M 130 230 NA Distal ICA stenosis 3 23 2 1 No
20/67/M 130 NA NA NA NA 4 30 6 Sym
21/71/F 70 160 1,000,000 Distal ICA 1 23 NA 6 Sym
22/59/F 170 290 NA Normal 3 21 1 1 No
23/80/M 160 NA NA NA NA 16 4 1 No
24/60/F 170 310 500,000 M1 0 17 15 4 Asym
25/59/M 110 230 NA Cervical ICA 0 22 NA 2 No
26/54/M 150 275 500,000 Distal ICA 3 20 4 1 No
27/72/F 150 255 NA PCA 0 17 3 1 No
28/58/F 180 265 500,000 M1 3 13 0 0 No
29/57/M 135 NA NA NA NA 8 1 1 No
30/81/M 150 250 NA BA stenosis 3 24 1 1 No
Note.—Asym indicates asymptomatic hemorrhagic transformation; DSA, digital subtraction angiography; M1, M1 segment of the MCA; M2, M2
segment of the MCA; NA, not applicable; and Sym, symptomatic hemorrhagic transformation.
* Time from recurrent symptoms after IV thrombolysis to angiography.
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were two patients with a cervical ICA occlusion, two
with normal angiographic findings, and four with
marked clinical improvement (stenosis of the relevant
arteries in three and distal branch occlusion in one)
during the diagnostic angiographic procedures (Fig
1). The total dose of UK ranged from 300,000 to
1,000,000 U (median, 600,000 U). IV abciximab was
administrated in four patients (patients 3, 7, 10, and
28) who had a reocclusion immediately after initially
successful thrombolysis (Table 1). The reoccluded
arteries regained full reperfusion within 60 minutes
after abciximab infusion.
Arterial Recanalization
In 24 patients who underwent cerebral angiogra-
phy, TIMI grade 3 flow was observed in 14 (58%),
and TIMI grade 2 flow was observed in three (12%).
The MCA had a successful recanalization of TIMI
grade 3 or 2 flow in 11 of 13 patients. The BA was
recanalized in all three patients, and the ICA was
recanalized in three of seven patients (Table 2). In 16
patients treated with combined thrombolysis, TIMI
grade 3 flow was achieved in nine (56%), and TIMI
grade 2 flow was achieved in three (18%).
Clinical Outcomes
The median baseline NIHSS score was 18 (range,
4–30) in 30 patients. At 30 days, the score could be
assessed in 26 patients; the median was 2 (range,
0–30) (Fig 2). An improvement in the NIHSS score to
4 was observed in 23 patients. About 60% (18 pa-
tients) had a good functional outcome defined as an
mRS score of 0 or 1 at 90 days. Twelve (70%) of 17
patients with a successful recanalization (TIMI grade
2 or 3) and two (28%) of seven with an unsuccessful
recanalization (TIMI 0 or 1) had an mRS score of 0
or 1 at 90 days. The mortality rate after 90 days of
follow-up was 10% (three of 30 patients). One patient
died from an intracranial hemorrhage, and the other
two died after discharge due to undefined causes.
Hemorrhagic Transformation
HT was observed in seven patients (23%). Six de-
veloped in those receiving combined IV rTPA and IA
UK, and one affected a patient receiving IV rTPA.
No HT was observed in those treated with abciximab.
Clinical deterioration due to HT occurred in two
patients (one from the IV rTPA group and the other
from the combined IV rTPA and IA UK group) and
led to death in one patient. Six patients who under-
went angiography during thrombolysis had HT: four
(57%, TIMI grade 0 in three and TIMI grade 1 in
one) of seven patients with unsuccessful recanaliza-
tion and two (11%; TIMI grade 2 in one and TIMI
grade 3 in one) of 17 patients with successful recan-
alization (P  .05).
Discussion
Although thrombolytic therapy is effective in re-
ducing the neurologic deficits in acute ischemic
stroke, thrombolysis fails in a considerable proportion
of patients. Combined IV and IA thrombolysis may
have benefits because a high recanalization rate is
expected with IA thrombolysis, in addition to the fast
and easy introduction of the thrombolytic agent via
the IV route. Although different thrombolytic regi-
mens and strategies for combined thrombolysis have
been examined and are under investigation, this study
differs from previous or ongoing studies in several
points. In this study, the UK was combined with
rTPA, whereas others used rTPA for both the IV and
the IA approaches. The sequential combination of
rTPA and UK/pro-UK has complementary and syn-
ergistic effects on clot lysis (17). The fibrin selectivity
of UK/pro-UK is attributed to its selective activation
of fibrin-bound plasminogen, whereas TPA directly
binds strongly to fibrin. Predigestion of a thrombus by
TPA exposes the plasminogen binding sites, which
are required for the action of UK/pro-UK. Therefore,
thrombolysis may be more efficient when TPA is
followed by a UK/pro-UK infusion, as was shown in
experimental studies and in patients with acute coro-
nary artery disease (14–16).
IA thrombolysis was attempted in patients who did
not have an early clinical response to a full dose of
FIG 2. Baseline and 30-day NIHSS scores. Median scores
were 18 and 2, respectively






UK 0 1 2 3
ICA (n  7) 3 4 3 1 1 2
MCA (n  13) 3 10 2 0 2 9
BA (n  3) 1 2 0 0 0 3
PCA (n  1) 1 0 1 0 0 0
Total (n  24) 8 16 6 (25%) 1 (4%) 3 (12%) 14 (58%)
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rTPA. In the Emergency Management of Stroke
(EMS) bridging trial (7), two-thirds (0.6 mg/kg) of the
dose used in the NINDS trial for IV rTPA (0.9 mg/kg)
was used for the IV thrombolysis portion, and a max-
imum dose of 20 mg rTPA was used for subsequent
IA thrombolysis. The IV infusion time was also short-
ened (from 60 to 30 minutes). A similar dose regimen
has been used in other trials (8, 10). In the ongoing
Interventional Management of Stroke (IMS) study
(18), the IV thrombolysis by using the same dose and
infusion time of rTPA as in the EMS bridging trial
was followed as soon as possible by cerebral angiog-
raphy. The indication for the IA approach was the
presence of thrombus. In this study, patients who did
not have an early clinical response to a full dose of IV
rTPA were given further treatment with IA throm-
bolysis. With this approach, some patients who im-
prove early after IV rTPA therapy may avoid an
unnecessary IA procedure. In this study, five patients
had so improved after rTPA infusion that angiogra-
phy for IA thrombolysis was not performed. Further-
more, IA UK infusion was unnecessary in four pa-
tients because of marked improvement in the
angiographic suite. Therefore, angiography or IA UK
infusion, which can cause angiographic complications
or additional risks of hemorrhage, were avoidable in
30% of patients. However, in this study, the median
delay from the IV rTPA bolus to angiography was 1
hour 35 minutes. In the IMS trial (18), the delay was
approximately 40 minutes. In this regard, the strategy
of fast angiography to identify a thrombus as a ther-
apeutic target in the IMS study may shorten the
access time to additional thrombolytic therapy.
Finally, the study protocol included evaluation and
treatment of reocclusion, which can occur during or
immediately after an initially successful thrombolysis
(19). Abciximab, a potent and specific platelet glyco-
protein IIb/IIIa receptor inhibitor, has been effective
in resolving recurrent thrombosis after thrombolytic-
induced thrombolysis in individuals with acute myo-
cardial infarction or ischemic stroke, as this type of
rethrombosis has platelet-mediated thrombotic
mechanisms (20–23). As was shown in this study and
a previous report (19), reocclusion can be completely
and safely resolved with abciximab. Although the
safety and efficacy of widespread use of abciximab in
acute stroke awaits the final results of ongoing studies
(24), its selective use may be beneficial in patients
with reocclusion.
Combined thrombolysis may have the benefits of high
complete recanalization rate and improved patient out-
comes. Recanalization to TIMI grade 3 flow was
achieved in more than one-half of patients in this study;
this rate was similar to those of previous studies of
combined IV/IA thrombolysis. In the present study, fa-
vorable functional outcomes of 90-day mRS scores of 0
or 1 were achieved in 60% of patients. This rate was
higher than those observed in studies examining the
effect of pure IA or IV thrombolysis: for IA therapy:
26% in Prolyse in Acute Cerebral Thromboembolism
(PROACT) II study for IA therapy and for IV therapy,
39% in the NINDS rTPA study, and 35.7% in the
European Cooperative Acute Stroke Study (ECASS)
(1, 5, 25). Reported rates of favorable outcomes, 25–
77% in previous combined IV/IA thrombolysis trials,
are comparable to ours (7–11).
Hemorrhage is one of major negating factors of
thrombolytic therapy, as it diminished the effect of
thrombolysis and limits the enrollment of patients
because of the risk of hemorrhage. HT was a major
concern in this study because UK was administrated
in addition to a conventional dose of rTPA. Although
six of the seven patients with HT were treated with
combined thrombolysis, the HT rate was similar to
those in the previous studies or trials. In comparison
data from a single center, no significant difference
was found between the agents (rTPA vs UK) and the
route of thrombolytics (IA vs combined IV/IA) (26).
An increased dose of IV rTPA was suggested to
increase the risk of hemorrhage in a small pilot study
performed before the larger NINDS rTPA study (27);
however, the effect of sequentially administrated UK
(which reacts to a receptor different than that tar-
geted by rTPA) on the development of HT is unclear.
Several studies have identified factors that may lead
to HT after thrombolysis. In an analysis of the data from
the European Cooperative Acute Stroke Study and the
NINDS Stroke Study, several factors were associated
with HT: severe neurologic deficits; increasing age; and
early ischemic changes, brain edema, or mass effect at
CT (28, 29). Increased glucose level, high NIHSS score,
prolonged time to recanalization, less recanalization,
and low platelet counts were independent predictors of
HT in IA thrombolysis trials (26). Although these re-
sults suggest that no single clinical factor predicts the
development of HT, vessel-wall damage that leads to
HT is mediated by matrix metalloproteinase-9, a pro-
teolytic enzyme that degrades the major extracellular
matrix components of the vessel wall (30). Increased
baseline plasma levels of this metalloproteinase before
thrombolysis are associated with the development of
HT and a failure of thrombolysis (31, 32). This obser-
vation may partly account for the increased rate of HT
in our patients with poor recanalization.
This study had several limitations. First, a small
number of patients enrolled, and there was no control
group. Second, the sizes and sites of the occluded
arteries were heterogeneous. However, this study
showed that UK, which is known to be synergistic
with and complementary to rTPA, may be safely and
effectively administrated by the IA route in acute
ischemic stroke without an early clinical response to
conventional IV rTPA treatment.
Conclusion
In this pilot study, a full dose of IV rTPA and a
sequential combination of IA UK for patients without
an early clinical response to the IV approach was
feasible and safe. This approach had high recanaliza-
tion rates, good functional outcomes, and acceptable
mortality and hemorrhage rates. However, because of
the small number of patients, the lack of a control
group, and the presence of heterogeneous arterial
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lesions, further large-scale studies are needed to con-
firm these results.
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